Pratibha Sharma has withdrawn her consent to act as the Company Secretary and Compliance Officer of Hemo Organic Limited. Consequently, the proposed appointment for this role has not taken effect, leaving the position vacant.

The company informed BSE Limited on October 14, 2026, regarding the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sharma confirmed that there were no material reasons for her decision to withdraw consent from the said position.

Regulatory compliance and next steps

Hemo Organic stated it will take necessary steps to appoint a suitable candidate for the Company Secretary and Compliance Officer role. This process will adhere to the applicable provisions of the Companies Act, 2013, and the SEBI Listing Regulations. The company intends to intimate the stock exchange about the new appointment in due course.

Disclosure details

The following table summarizes the key particulars disclosed in the regulatory filing:

The disclosure was made pursuant to SEBI circular guidelines dated January 30, 2026, ensuring transparency in corporate governance changes.

Hemo Organic Limited's Board of Directors deferred its proposal for raising funds during the meeting held on October 3, 2026. The decision was taken after due discussion, with no approval granted for the issuance of equity shares or convertible securities at this stage.

The company stated that the fund raising proposal has been moved to a subsequent meeting of the Board. Hemo Organic will make further disclosures regarding the date and time of the next Board meeting as and when decided, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Authorized Share Capital Increase

Despite deferring the immediate fund raise, the Board approved a significant increase in the company's authorized share capital. The authorized capital will rise from ₹13.45 crore to ₹125 crore. This expansion involves increasing the number of equity shares from 1,34,50,000 to 12,50,00,000, each with a face value of ₹10.

This increase is subject to the approval of shareholders and subsequent alteration of Clause 5 of the Memorandum of Association.

Alteration of Main Objects

The Board also approved the alteration of the Main Objects clause in the Memorandum of Association. The revised objects include:

• Trading, dealing, and distributing diamonds, including rough, polished, natural, and laboratory-grown diamonds.
• Cutting, polishing, processing, and manufacturing diamond-related products.
• Acquiring, developing, and managing real estate properties for investment or income generation.
• Investing in shares, stocks, or assets of entities engaged in the aforementioned activities.

Corporate Governance Updates

Ms. Pratibha Sharma was appointed as the Company Secretary and Compliance Officer effective October 3, 2026. She is an associate member of the Institute of Company Secretaries of India (ICSI) with experience in company law, corporate governance, and regulatory compliance.

Regulatory Compliance and Trading Window

The intimation was filed with BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting was held at the registered office in Ahmedabad, Gujarat.

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons remained closed from September 29, 2026, until 48 hours after the declaration of financial results for the quarter and half-year ended September 2026.

Meeting Outcome Summary

What the Numbers Show

The authorized share capital increase represents a nearly 9.3x expansion from ₹13.45 crore to ₹125 crore. This substantial headroom creation precedes any actual fund raising, suggesting the company is preparing for potential large-scale capital infusion or strategic acquisitions in the future, particularly given the new object clauses covering diamonds and real estate.